Evidence map›Paper›PMID 27893710›Full record

ArticleOncogene2017

MUC1-C activates BMI1 in human cancer cells.

M Hiraki, T Maeda, A Bouillez, M Alam, A Tagde, K Hinohara, Y Suzuki, T Markert, M Miyo, K Komura and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. The multifaceted role of MUC1 in tumor therapy resistance.Clinical and experimental medicine · 2023
    Review
  12. Article
  13. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Emergence ofCancers · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

M HirakiMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
T MaedaMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
A BouillezMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M AlamMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
A TagdeMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
K HinoharaMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Y SuzukiMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
T MarkertMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M MiyoMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
K KomuraMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
R AhmadMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
H RajabiMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
D KufeMedical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Harvard University · USDana-Farber Cancer Institute · US

Funding

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast CancerR01CA097098 · NCI · DANA-FARBER CANCER INSTITUTE · PI DONALD W. KUFE · 2002 to 2026
$8.8M
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3M
NCI NIH HHS R01 CA097098NCI NIH HHS R01 CA166480
6 · The paper itself

Abstract

B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overexpressed in human carcinoma cells and has been linked to their self-renewal. There is no known relationship between MUC1-C and BMI1 in cancer. The present studies demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism in breast and other cancer cells. In addition, we show that MUC1-C blocks miR-200c-mediated downregulation of BMI1 expression. The functional significance of this MUC1-C→︀BMI1 pathway is supported by the demonstration that targeting MUC1-C suppresses BMI1-induced ubiquitylation of H2A and thereby derepresses homeobox HOXC5 and HOXC13 gene expression. Notably, our results further show that MUC1-C binds directly to BMI1 and promotes occupancy of BMI1 on the CDKN2A promoter. In concert with BMI1-induced repression of the p16

Indexed as

Amino Acid MotifsAmino Acid SequenceCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Gene Expression Regulation, NeoplasticGene SilencingHistonesHomeodomain ProteinsHumansMucin-1NeoplasmsNF-kappa BPolycomb Repressive Complex 1Promoter Regions, GeneticProtein BindingProtein Interaction Domains and MotifsBMI1 protein, humanCyclin-Dependent Kinase Inhibitor p16HistonesHomeodomain ProteinsMucin-1NF-kappa BPolycomb Repressive Complex 1Proto-Oncogene Proteins c-myc

Identifiers

PMID27893710
PMCPMC5436937
OpenAlexW2557697459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.